This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kathryn E. Richert-Boe, MD; Linda L. Humphrey, MD, MPH

Arch Intern Med. 1992;152(12):2398-2404.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Lung and colorectal cancer are the first and second lead. ing causes of death from cancer among Americans. It is only natural that there should be considerable interest in trying to prevent deaths from these diseases through early detection and treatment. However, widespread screening is expensive and logistically difficult, therefore the ability of screening tests to reduce cancer mortality must be well established before they are put into common practice. The basic principles of screening, including the characteristics of diseases and tests suitable for screening, biases that can affect uncontrolled studies of screening tests, and costs of screening are discussed in part 2 of this article.¹

In this article, we critically analyze the data regarding the effectiveness of screening tests in reducing mortality from lung and colorectal cancer and discuss the controversies surrounding their use. As in our previous article, the quality of the data for each test will . . . [Full Text PDF of this Article]

Author Affiliations
From the Sections of Hematology and Medical Oncology (Dr RichertBoe) and General Internal Medicine (Dr Humphrey), Medical Service, Department of Veterans Affairs Medical Center and the Department of Medicine, The Oregon Health Sciences University, Portland.

Footnotes
Accepted for publication May 29, 1992.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?